KR20130092976A - 시각 장애를 치료하기 위한 조성물 및 방법 - Google Patents

시각 장애를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20130092976A
KR20130092976A KR1020127029867A KR20127029867A KR20130092976A KR 20130092976 A KR20130092976 A KR 20130092976A KR 1020127029867 A KR1020127029867 A KR 1020127029867A KR 20127029867 A KR20127029867 A KR 20127029867A KR 20130092976 A KR20130092976 A KR 20130092976A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
retinal
oil
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127029867A
Other languages
English (en)
Korean (ko)
Inventor
우르술라 브이. 스토브리
용-신 리
앨런 씨. 포스터
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20130092976A publication Critical patent/KR20130092976A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020127029867A 2010-04-15 2011-04-13 시각 장애를 치료하기 위한 조성물 및 방법 Withdrawn KR20130092976A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32463210P 2010-04-15 2010-04-15
US61/324,632 2010-04-15
PCT/US2011/032325 WO2011130411A1 (en) 2010-04-15 2011-04-13 Compositions and methods for treating visual disorders

Publications (1)

Publication Number Publication Date
KR20130092976A true KR20130092976A (ko) 2013-08-21

Family

ID=44009992

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127029867A Withdrawn KR20130092976A (ko) 2010-04-15 2011-04-13 시각 장애를 치료하기 위한 조성물 및 방법

Country Status (8)

Country Link
US (1) US20110257186A1 (https=)
EP (1) EP2558100A1 (https=)
JP (1) JP2013523892A (https=)
KR (1) KR20130092976A (https=)
AU (1) AU2011239683A1 (https=)
CA (1) CA2796345A1 (https=)
RU (1) RU2012148214A (https=)
WO (1) WO2011130411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600127037A1 (it) * 2016-12-15 2018-06-15 Oftalab S R L Soluzione oftalmica di verde di lissamina e suo uso in oftalmologia
CN109908327A (zh) * 2019-03-12 2019-06-21 广州陈锦济生物科技有限公司 一种用于治疗近视的眼药水及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
KR20050094840A (ko) * 2003-01-13 2005-09-28 코텍스 파마슈티칼스, 인크. 수면 부족 및 스트레스로 인한 인식 저하의 치료방법
WO2007124348A2 (en) * 2006-04-20 2007-11-01 The Regents Of The University Of California Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
WO2008060375A2 (en) * 2006-10-06 2008-05-22 The Regents Of The University Of Californina Upregulating bdnf levels to mitigate mental retardation
BRPI0720323A2 (pt) 2007-01-03 2016-08-09 Cortex Pharma Inc composto, método de tratamento, composição farmacêutica e uso do composto
GEP20125438B (en) * 2007-01-03 2012-03-26 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
KR20100063087A (ko) * 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논

Also Published As

Publication number Publication date
US20110257186A1 (en) 2011-10-20
WO2011130411A1 (en) 2011-10-20
CA2796345A1 (en) 2011-10-20
RU2012148214A (ru) 2014-05-20
AU2011239683A1 (en) 2012-11-08
JP2013523892A (ja) 2013-06-17
EP2558100A1 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
JP2011502990A (ja) 薬物送達用ビヒクルとしての水非混和性物質
NZ725574A (en) Compounds for treating ophthalmic diseases and disorders
JP2008520671A (ja) 眼科用組成物および眼の治療方法
NZ283658A (en) Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
KR20100072333A (ko) 약물 전달을 위한 비히클로서의 비-수성 수혼화성 물질
JP2021518352A (ja) チモロールを含む医薬組成物
Henderer et al. Ocular pharmacology
EP0451082B1 (en) Ophthalmic product
WO2005055926A2 (en) Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US20170172959A1 (en) D-serine for the treatment of visual system disorders
KR20130092976A (ko) 시각 장애를 치료하기 위한 조성물 및 방법
DE69332055T2 (de) Zusammensetzung von Argatroban zur Verwendung in Ophthalmologie
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
CA2442296C (en) Therapeutic agents for retinochoroidal disorders comprising steroids as active ingredients
JP2002356431A (ja) ステロイドを有効成分とする網脈絡膜疾患治療剤
CA2817505C (en) Pharmaceutical formulation having neuroprotective activity
KR20070018755A (ko) 무스카린 수용체 작동약을 함유한 안과용 경피흡수형 제제
US20130197002A1 (en) Brimonidine for treating visual disorders mediated by central visual projections from the eye
JP2007056012A (ja) 軟膏様組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121114

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid